profit from every $100 of sales.
$0$100
Turn Therapeutics
$10.13-4.16% today
+130.2% in 1 year
1-year low $2.711-year high $15.34
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Turn Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2023 to $0 in 2024, with -$1.77 million of profit last year.
SalesProfit
Turn Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Turn Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads Turn Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2023 | 2024 |
|---|---|---|
| 0 | 0 | |
| – | – | |
| -2 | -2 | |
| -2 | -2 | |
| -2 | -2 | |
| -0.08 | -0.06 | |
| – | – | |
| – | – | |
| – | – |
Balance sheet
| In millions of USD | 2023 | 2024 |
|---|---|---|
| Total assets | 2 | 2 |
| Cash | 1 | 1 |
| Total debt | 0 | 0 |
| Total liabilities | 2 | 2 |
| 0 | -0 | |
| 29 | 29 | |
| -1,643.9% | – | |
| -2,672.6% | 996.7% |
Cash flow
| In millions of USD | 2023 | 2024 |
|---|---|---|
| -1 | -1 | |
| 0 | 0 | |
| -1 | -1 | |
| Dividends paid | – | – |
| – | – | |
| 1 | 0 |
Valuation
- –
- –
- –
- 11.9×
- –
- –
- –
- -0.9%
- -1.0%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -94.4%
- 334.1%
- -141.7%
- -26.3%
- -95.1%
- –
Growth
- –
- –
- −85.9%
- –
- +1.9%
Financial health
- 0.9×
- 0.02
- 0.7%
- –
- 0.87
- 0.87
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 952
Bottom 20%of 883
Bottom 34%of 985
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 11, 2026 | -0.03 | -0.02 | −50.0% |
| Mar 31, 2026 | -0.09 | -0.05 | −76.5% |
| Nov 13, 2025 | -0.07 | – | – |
News
AI Infrastructure Numbers Keep Climbing While the Week's Headlines Turn to the BoardroomYahoo Finance · Nov 12, 2026Manchester United sacks its manager as it looks to turn around a woeful seasonSeeking Alpha · Nov 12, 2026NVDA Fallout Pressures Tech Trade As Investors Turn To Cerebras, Applied Materials For Chip Demand CuesYahoo Finance · Nov 12, 2026Trump defends Jensen Huang, but other Republicans could turn up the pressure quicklyYahoo Finance · Nov 9, 2026Hamilton Beach Brands expects 2026 revenue to be flat as retailers turn cautiousSeeking Alpha · Nov 5, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
20No pass
Benjamin Graham
25No pass
Philip Fisher
38No pass
Peter Lynch
62Pass
Joel Greenblatt
2No pass
Charlie Munger
27No pass
Terry Smith
24No pass
Questions about Turn Therapeutics
Is Turn Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Turn Therapeutics AI analysis
What does Turn Therapeutics do?
Global Health Solutions, Inc., doing business as Turn Therapeutics, operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. It is in Biotechnology.
Does Turn Therapeutics pay a dividend?
No. Turn Therapeutics does not pay a dividend at the moment.
Is Turn Therapeutics stock halal?
Yes. Turn Therapeutics passes our halal screen: its business is permitted and its debt is under 0.1% of its market value, under the 30% limit. How we check
How has Turn Therapeutics stock done over the past year?
Up 130.2% over the past twelve months, to $10.13. It traded between $2.71 and $15.34 and is 34.0% below its high.
Who are Turn Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Turn Therapeutics's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.